文献速递炎症性肠病

NFkB、TNF-α、IL-1β及IL-18通路基因多态性与丹麦炎症性肠病患者抗TNF治疗应答的关联

Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-02-27

在队列2(587例克罗恩病、458例溃疡性结肠炎)中对53个单核苷酸多态性(SNP)进行基因分型,采用校正年龄和性别的逻辑回归分析。10个SNP与抗TNF治疗应答相关,涉及NFκB通路(TLR2、TLR4、NFKBIA)、TNF-α信号通路(TNFRSF1A)及其他细胞因子通路(NLRP3、IL1RN、IL18、JAK2)。多SNP模型在部分克罗恩病患者中预测应答率超过82%,在部分溃疡性结肠炎患者中为75%,而全部克罗恩病和溃疡性结肠炎患者的应答率分别为71%和64%。作者认为需要更多研究来预测应答以用于临床。

要点

  • 在队列2中,10个SNP与抗TNF治疗应答相关,涉及NFκB、TNF-α及其他细胞因子通路。
  • 克罗恩病中TNFRSF1A(rs4149570) OR为1.92(95%CI 1.02-3.60,P=0.04)。
  • 溃疡性结肠炎中TLR4(rs5030728) OR为2.23(95%CI 1.24-4.01,P=0.01)。

核心结论

  • 结果支持NFκB通路(TLR2、TLR4、NFKBIA)、TNF-α信号通路(TNFRSF1A)及其他细胞因子通路(NLRP3、IL1RN、IL18、JAK2)基因多态性与抗TNF治疗应答相关。
  • 作者认为需要更多研究来预测应答以用于临床。

研究设计与样本

  • 建立新队列(队列2)以重复验证既往发现并识别新的与抗TNF应答相关的SNP。
  • 在队列2(587例克罗恩病和458例溃疡性结肠炎患者)中对既往在队列1(482例克罗恩病和256例溃疡性结肠炎患者)评估过的53个SNP进行基因分型。
  • 采用逻辑回归分析(校正年龄和性别)。

主要发现

  • 克罗恩病中:TNFRSF1A(rs4149570) OR为1.92(95%CI 1.02-3.60,P=0.04),IL18(rs187238) OR为1.35(95%CI 1.00-1.82,P=0.05),JAK2(rs12343867) OR为1.35(95%CI 1.02-1.78,P=0.03)。
  • 溃疡性结肠炎中:TLR2(rs11938228) OR为0.55(95%CI 0.33-0.92,P=0.02),TLR4(rs5030728) OR为2.23(95%CI 1.24-4.01,P=0.01),TLR4(rs1554973) OR为0.49(95%CI 0.27-0.90,P=0.02),NFKBIA(rs696) OR为1.45(95%CI 1.06-2.00,P=0.02),NLRP3(rs4612666) OR为0.63(95%CI 0.44-0.91,P=0.01)。
  • 克罗恩病与溃疡性结肠炎合并队列中:TLR4(rs5030728) OR为1.46(95%CI 1.01-2.11,P=0.04),TLR4(rs1554973) OR为0.80(95%CI 0.65-0.98,P=0.03),NFKBIA(rs696) OR为1.25(95%CI 1.01-1.54,P=0.04),NLRP3(rs4612666) OR为0.73(95%CI 0.57-0.95,P=0.02),IL1RN(rs4251961) OR为0.81(95%CI 0.66-1.00,P=0.05),IL18(rs1946518) OR为1.24(95%CI 1.01-1.53,P=0.04),JAK2(rs12343867) OR为1.24(95%CI 1.01-1.53,P=0.04)。
  • 多SNP模型在9%的克罗恩病患者中预测应答率超过82%,在15%的溃疡性结肠炎患者中预测应答率为75%,而全部克罗恩病和溃疡性结肠炎患者的应答率分别为71%和64%。

局限性

  • 作者指出需要更多研究来预测应答以用于临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-tumor necrosis factor-α (TNF-α) is used for the treatment of severe cases of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). However, one-third of the patients do not respond to the treatment. We have previously investigated whether single nucleotide polymorphisms (SNPs) in genes involved in inflammation were associated with response to anti-TNF therapy among patients with CD or UC. AIM: A new cohort of patients was established for replication of the previous findings and to identify new SNPs associated with anti-TNF response. METHODS: Fifty-three SNPs assessed previously in cohort 1 (482 CD and 256 UC patients) were genotyped in cohort 2 (587 CD and 458 UC patients). The results were analysed using logistic regression (adjusted for age and gender). RESULTS: Ten SNPs were associated with anti-TNF response either among patients with CD (TNFRSF1A(rs4149570) (OR: 1.92, 95% CI: 1.02-3.60, P = 0.04), IL18(rs187238) (OR: 1.35, 95% CI: 1.00-1.82, P = 0.05), and JAK2(rs12343867) (OR: 1.35, 95% CI: 1.02-1.78, P = 0.03)), UC (TLR2(rs11938228) (OR: 0.55, 95% CI: 0.33-0.92, P = 0.02), TLR4(rs5030728) (OR: 2.23, 95% CI: 1.24-4.01, P = 0.01) and (rs1554973) (OR: 0.49, 95% CI: 0.27-0.90, P = 0.02), NFKBIA(rs696) (OR: 1.45, 95% CI: 1.06-2.00, P = 0.02), and NLRP3(rs4612666) (OR: 0.63, 95% CI: 0.44-0.91, P = 0.01)) or in the combined cohort of patient with CD and UC (IBD) (TLR4(rs5030728) (OR: 1.46, 95% CI: 1.01-2.11, P = 0.04) and (rs1554973)(OR: 0.80, 95% CI: 0.65-0.98, P = 0.03), NFKBIA(rs696) (OR: 1.25, 95% CI: 1.01-1.54, P = 0.04), NLRP3(rs4612666) (OR: 0.73, 95% CI: 0.57-0.95, P = 0.02), IL1RN(rs4251961) (OR: 0.81, 95% CI: 0.66-1.00, P = 0.05), IL18(rs1946518) (OR: 1.24, 95% CI: 1.01-1.53, P = 0.04), and JAK2(rs12343867) (OR: 1.24, 95% CI: 1.01-1.53, P = 0.04)). CONCLUSIONS: The results support that polymorphisms in genes involved in the regulation of the NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signalling pathway (TNFRSF1A), and other cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF therapy. Our multi-SNP model predicted response rate of more than 82% (in 9% of the CD patients) and 75% (in 15% of the UC patients), compared to 71% and 64% in all CD and UC patients, respectively. More studies are warranted to predict response for use in the clinic.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bank S, Julsgaard M, Abed OK, et al. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019. PMID: 30811631. doi:10.1111/apt.15187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。